1 / 19

ACUTE LYMPHOBLASTIC LEUKEMIA STUDY GROUP OF INDIA ALL SGI

ACUTE LYMPHOBLASTIC LEUKEMIA STUDY GROUP OF INDIA ALL SGI. Dr Suresh Advani Mumbai , INDIA. ALL MAGNITUDE OF PROBLEM IN INDIA. Population : 1 Billion + Pop. < 18 yrs : 40 % New cases/ yr : ~ 8000 Per capita GNP : US $ 350 National Priority : ID & Nutritional Diseases

guiliaine-connor
Download Presentation

ACUTE LYMPHOBLASTIC LEUKEMIA STUDY GROUP OF INDIA ALL SGI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ACUTE LYMPHOBLASTIC LEUKEMIASTUDY GROUP OF INDIAALL SGI Dr Suresh Advani Mumbai , INDIA.

  2. ALLMAGNITUDE OF PROBLEM IN INDIA Population : 1 Billion + Pop. < 18 yrs : 40 % New cases/ yr : ~ 8000 Per capita GNP : US $ 350 National Priority : ID & Nutritional Diseases 1 in 7 people in the world, Indian!

  3. ALL IN INDIA: FACTS • ~ 8000 new cases/yr;< 1000 adequately Rxed • Mostly Morphological diagnosis No National data available • Tough > 70% cured in West, in India except in major centres results still very poor. • Cost of Rx : $ 1500; affordability 70/2 5/5 Access to Rx : PCUs; infrastructure Most are HR : late presentation; biology? Females under represented

  4. ALL IN INDIA - BACKGROUND • Before 90’s : Survival rate of < 30 % • Rx not organized • Criteria for protocol entry not well defined • Diff. protocols used even in same Institution! • 1st effort to organize ALL Rx was by Dr Ian Magrath: The NCI initiative : 1985 ACI; TMH; AIIMS

  5. ACUTE LYMPHOBLASTIC LEUKEMIA (MCP 841) OAS 1990-97 1.0 .9 .8 .7 .6 Survival .5 .4 .3 .2 .1 0.0 0 2 4 6 8 10 12 YEARS OAS 65.5 % n=688

  6. All IN INDIA: NCI INITIATIVE • Helped to: • organize Rx for ALL • develop infrastructure • Rx patients uniformly- inside/outside • anticipate problems & deal with them • identify some prognostic factors • The success with MCP 841 protocol at the National level has been the impetus to form the ALLSGI !

  7. ALLSGI: FORMATION Jan 27, 2001 : Pre ISMPO; Hyderabad Why now? • More trained Onc’s: Many trained with us • PCU’s increasing • SIOP Initiative: Training of Ped’s • INCTR Initiative: expertise, training, res. • Better Communication & Transport

  8. ALL SGI : INITIAL OBJECTIVES • To get organized • To get used to data collection • Identifying participating centers • Try to develop infrastructure at participating centers (Dx; Nursing; BB;Microbiology) Chalk out short term objectives & long term goals!

  9. ALL SGI: FORMATION OF ZONES India is Big Country: Many centers, Many Pts North Zone : AIIMS, Delhi East Zone : KMC, Calcutta South Zone : ACI,Chennai West Zone : TMH, Mumbai Central data collection & Monitoring unit

  10. ALL SGIWhat Have We Achieved So Far • -Data of >2000 patients treated uniformly on a single protocol • Publications from individual centres • Publications of data as a group

  11. Event-Free Survival by Center TMH Percent Event Free Survival AIIMS CI Years since start oftherapy

  12. Risk Factors (EFS): Multivariate Analysis • WBC at AIIMS and Mumbai (p=0.0005 and 0.002 respectively), not at CI • But best risk group still < 70% EFS • No significant risk factors could be identified at Chennai – nor in Pre B or Pre-T separately • No very high or very low risk groups identifiable at all three centers • Early response not studied Extensive analysis performed by experienced NCI statisticians

  13. Temporal Changes with Identical Protocol 1995-96 1989-90 Percent Event Free Survival 1991-92, 93-94 1986-87 TMH: 2 yr intervals 101-163 patients per group Years since start oftherapy A: 1986-87 B: 1988-90 C: 1991-92 D: 1993-94 E: 1995-96 F: 1997

  14. Translocations in ALL Childhood , USA

  15. ALL SGI TO WRITE GRANTS Grant from Lady Ratan Tata Trust For : Developing the Cooperative Group To Write Grants For: Epidemological studies: Clinical & Molecular Clinical studies Lab studies: Pathogenesis, Mol. Biology Preventive Aspects

  16. ALL SGI ALL TREATMENT • Develop infrastructure • Rx data initially only from limited centers • To continue established protocol (e.g. MCP 841) at these centers • Investigational protocol(e.g. MCP 943) only at zonal centers • Highest quality of information must be assured: Diag, data collection, data analysis Once group established, only then to think about ALL National Protocol- keeping in mind simplicity & cost!

  17. ALL SGILONG TERM GOALS: RESEARCH INITIATIVES • Is ALL in India Biologically different? • Std risk factors do not show diff in outcome • many remission deaths • Delays in Rx: hepatitis, toxicity,etc • Socioeconomic risk profile • Toxicity profile: • Nutritional status • Pharmacokinetics, Pharmacogenomics Difference in Leukemic cell or Patient ??

  18. ALL : FUTURE PLANS

More Related